Post-IPO Equity - Audentes Therapeutics
Investment Firm
Overview
Audentes is a biotechnology company that employs gene therapy technology to develop treatments for people with rare muscle diseases.
Announced Date
Oct 10, 2018
Funding Type
Post Ipo Equity
Highlights
Location
United States, North America
Social
Investor Lead
N/A
Participant Investors
1
| Investor Name |
|---|
 Envision Capital Management |
Round Details and Background
Audentes Therapeutics raised $150800000 on 2018-10-10 in Post-IPO Equity
Audentes is a biotechnology company that employs gene therapy technology to develop treatments for people with rare muscle diseases.
Company Funding History
7
| Announcment Date | Transaction Name | Number Of Investors | Lead Investor | Money Raised |
|---|---|---|---|---|
| Aug 08, 2017 |  Post-IPO Equity - Audentes Therapeutics | - | 75.0M | |
| Oct 13, 2015 | Series C - Audentes Therapeutics | 13 | - | 65.0M |
| Dec 02, 2014 | Series B - Audentes Therapeutics | 6 | - | 42.5M |
| Jul 18, 2013 | Series A - Audentes Therapeutics | 3 | - | 30.0M |
Recent Activity
There is no recent news or activity for this profile.